January 8, 2024
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors and Strengthens Scientific Advisory Board with Three Accomplished Lung and Bladder Cancer Specialists
CatalYm Appoints Drug Development Leader Roy Baynes to its Board of Directors...
Read More
December 6, 2023
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and Urothelial Cancer at the ESMO Immuno-Oncology Congress 2023
CatalYm Presents Positive Phase 2a Outcome for Visugromab in Advanced NSCLC and...
Read More
October 27, 2023
12P Immuno-suppressive role of tumour-derived GDF-15 on myeloid cells
Schuberth-Wagner, C., Giese, I., Kist, M., Vashist, N., Genßler, S., Haack, B.,...
Read More
October 26, 2023
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination with Neoadjuvant Immunotherapy in Treatment-naive Muscle Invasive Bladder Cancer Patients
CatalYm commences Dosing in a Phase 2 Study with Visugromab in Combination...
Read More
October 16, 2023
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation
CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy...
Read More
October 12, 2023
Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance
Interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm / Drug Target...
Read More
October 12, 2023
Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment
Markus Haake, Beatrice Haack, Tina Schäfer, Patrick N. Harter, Greta Mattavelli, Patrick...
Read More
July 20, 2023
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor of anti-PD-1 Resistance
CatalYm Publishes Data in Nature Communications Describing GDF-15 as a Central Factor...
Read More